Sign in

    Mia Bongiorno • Morgan Stanley

    Mia Bongiorno is an Equity Research Analyst at Morgan Stanley, specializing in Biotechnology Small & Midcap equities as part of the firm's acclaimed Extel All-America Research Team. She covers a range of biotech companies with a focus on small and mid-cap firms, helping inform investor decisions in a rapidly evolving sector. Bongiorno has been recognized through peer voting in industry research rankings, though public sources do not provide specific performance metrics or return data. Details of her career timeline, prior experience, and professional securities credentials are not available in current public disclosures.

    Mia Bongiorno's questions to Editas Medicine Inc (EDIT) leadership

    Mia Bongiorno's questions to Editas Medicine Inc (EDIT) leadership • Q2 2024

    Question

    Mia Bongiorno, on for Terence Flynn, asked about key learnings from the early launches of CASGEVY and Lyfgenia that Editas could apply to a future reni-cel launch.

    Answer

    Chief Commercial and Strategy Officer Caren Deardorf stated that Editas is encouraged by the launch progress of competitors, noting that its 'fast follower' timing is an advantage. This allows payers and treatment centers to establish processes, which should lead to a significantly shorter onboarding cycle for reni-cel at the time of its potential launch.

    Ask Fintool Equity Research AI